NVS
Novartis AG
NVS
Novartis AG
Dyne Therapeutics remains a Buy despite a 16% selloff triggered by Novartis' DM1 trial failure, which heightened platform-wide clinical risk perceptions. The Novartis HARBOR trial failure challenges t
Novartis shares plunged after late-stage failures of pelacarsen and del-desiran, impacting its long-term growth outlook. Despite setbacks, Novartis reiterated 2025-2030 revenue growth guidance of 5-6%
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
Oxford BioMedica PLC (LSE:OXB) received a reaffirmed 'outperform' rating from RBC Capital Markets on Friday, as the broker shrugged off clinical trial halts at two heavyweight pharmaceutical partners.
Genmab has underperformed so far this year despite strong commercial performance and largely positive pipeline news flow. Strong Q2 royalty product sales (Darzalex +18% Y/Y, Tecvayli +57% Y/Y) support
Novartis AG (NVS) Q2 2026 Earnings Call Transcript